Sakar Healthcare Signs 40th Anti-Cancer Product Agreement with Zydus Lifesciences for GCC and Emerging Markets

Sakar Healthcare Signs 40th Anti-Cancer Product Agreement with Zydus Lifesciences for GCC and Emerging Markets​

Sakar Healthcare Limited has announced a major strategic development, signing an agreement with Zydus Lifesciences. The agreement focuses on supplying oncology products within the Gulf Cooperation Council (GCC) and other emerging markets, marking a significant milestone for the company.

This partnership represents the 40th global agreement Sakar has secured for anti-cancer products, reinforcing its expanding presence in the global pharmaceutical supply chain.

Global Regulatory and Marketing Authorization Milestones​

The company detailed robust progress across its global regulatory filings, particularly within the European Union (EU) and in its API integration strategy.

Regarding Marketing Authorization (MA) filings in the EU, Sakar reported the following achievements:


Sakar also significantly advanced its regulatory footprint by addressing site variations across the EU. The company progressed on 33 site variations covering 18 cytotoxic molecules in markets including Germany, Italy, Norway, France, Finland, Sweden, Malta, Romania, and the UK.

Current site variation approvals include:

• 3 approvals by EMA (EU).
• 2 approvals by MHRA (UK).

Expanding API Capabilities and Integration​

On the Active Pharmaceutical Ingredient (API) side, Sakar emphasized the growth of its in-house development strategy. The company has developed 21 APIs, demonstrating its increasing control over the value chain. Of these, 16 APIs possess Written Confirmation, and 2 APIs have already secured CEP approvals. Additional CEP approvals are currently under review.

Mr. Sanjay Shah, Managing Director of Sakar Healthcare Limited, commented on these developments, stating, "These achievements underscore our focus on backward integration, strengthening regulatory capabilities, and expanding across global markets. We are encouraged by the progress in our regulatory approvals and API pipeline, supported by multiple approvals and a strong set of applications under review. This strengthens our ability to scale operations, enhance market share, and deliver meaningful revenue growth in the coming years."

SAKAR Stock Price Movement​

As of 2:08 PM, shares of Sakar Healthcare Limited are slipping by 2.61% in live trading, currently valued at ₹787.85. The stock experienced a substantial trading volume of 148,124 shares as the market progresses through the afternoon session.